RedHill Biopharma has filed with the U.S. Securities and Exchange Commission a non-public first draft registration statement to enable the listing of Company’s shares through a Level II ADR (American Depository Receipt) facility. Subject to receipt of relevant SEC and NASDAQ approvals and completion of the listing process, RedHill’s ADRs will be listed for trading on NASDAQ. RedHill recently reportedy positive results in three Multiple Sclerosis (MS) pre-clinical studies using the experimental autoimmune encephalomyelitis (EAE) MS model. The Company is in advanced preparations for a Phase IIa proof of concept clinical trial in Israel, to assess the efficacy and safety of its fixed dose oral drug combination, RHB-104, as an add-on therapy in patients treated for Relapsing Remitting MS. RedHill also recently reported the successful completion of two pivotal bioequivalence trials with RHB-102 for the prevention of nausea and vomiting in certain cancer patients and with RHB-103 an oral thin film for the treatment of acute migraine headaches. The Company is currently in preparations for the filing of U.S. FDA marketing applications with both products and is in preparations for late-stage (Phase III) clinical trials with other products.